- ￥1320
- BHcell（博辉生物）
- H-C122
- 2026年01月15日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
SK-N-BE(2)/SK-N-BE(2)细胞系/SK-N-BE(2)细胞株/SK-N-BE(2)人神经母细胞瘤细胞
Cell line name SK-N-BE(2)
Synonyms SK-N-BE2; SK-N-BE-2; SKNBE(2); SKNBE-2; SKNBE2; SK-N-BE; SKNBE
Accession CVCL_0528
Resource Identification Initiative To cite this cell line use: SK-N-BE(2) (RRID:CVCL_0528)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
From: Memorial Sloan Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-530.
Population: Caucasian.
Characteristics: Substrate-adherent type (S-type) (PubMed=15720811).
Doubling time: 27 hours (PubMed=29704); ~36 hours (DSMZ=ACC-632).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep tyrosine phosphoproteome analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DOI=10.1016/B978-0-12-333530-2.50006-X
Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York; USA (1994)
PubMed=7838528
Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995)
DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999)
PubMed=11507071
Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)
PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001)
PubMed=15720811; DOI=10.1593/neo.04310; PMCID=PMC1531688
Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F., Biedler J.L., Cheung N.-K.V., Ross R.A.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia 6:838-845(2004)
PubMed=15892104; DOI=10.1002/gcc.20198
Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K.A., Khazi D., Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L., Maris J.M.
High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Genes Chromosomes Cancer 43:390-403(2005)
PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20631050; DOI=10.1101/gr.106252.110; PMCID=PMC2928498
Storlazzi C.T., Lonoce A., Guastadisegni M.C., Trombetta D., D'Addabbo P., Daniele G., L'Abbate A., Macchia G., Surace C., Kok K., Ullmann R., Purgato S., Palumbo O., Carella M., Ambros P.F., Rocchi M.
Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure.
Genome Res. 20:1198-1206(2010)
PubMed=20655465; DOI=10.1016/j.cell.2010.06.004; PMCID=PMC2913027
Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N., Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C., Messiaen L.M., Versteeg R., Bernards R.
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.
Cell 142:218-229(2010)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由博辉生物科技（广州）有限公司提供； *发表【英文论文】请标注：From Bohui Biological Technology (Guangzhou) Co., Ltd.
刚开始养SK-BR-3时，细胞状态不是很好，贴壁也不均匀，于是开始想办法，考虑是不是吹打的不够，或是传得过多，或是其它的什么，后来发现的确如此，细胞的生长状态与传代的方法有很密切的联系。我的传代方法是：以50平方厘米培养瓶为例，待细胞长满瓶底70％－80％1 、吸除或倒掉瓶内旧培养基。2 、PBS 5ml加入培养瓶，轻轻晃动培养瓶，让PBS流遍细胞表面，倒掉。3 、PBS 5ml加入培养瓶重复洗一次，倒掉。4 、加入1ml胰蛋白酶消化液，轻轻摇动培养瓶，使消化液流遍所有细胞表面，然后置37度
细胞系开发和单克隆性的保证是生产生物药物分子（例如单克隆抗体）过程的关键步骤。该过程开始于将编码目的蛋白的基因递送至靶细胞。在分离出能稳定表达目的蛋白的单个活细胞之后便可建立细胞系。该过程中的一个重要里程碑是记录克隆性证明，以确保细胞系的遗传可复制性。随后的步骤包括对克隆进行表征以提高生产力（效价），质量和稳定性（图1）。当前细胞系开发中的工作流程具有许多限制，包括细胞活力低，单细胞分离效率低和克隆性证据有限。有限稀释的传统分离单个细胞的方法仅依赖于统计概率，并且没有可见的单克隆证据
kinase signalling cascades. Nature 410, 37–40. Coulomber, R.A. Jr, Drew, G.L., Stermitz, F.R., 1999. Pyrrolizidine alkaloids crosslink DNA with actin. Toxicol. Appl. Pharmacol.154, 198–202. Galan, A., Garcia-Bermejo, M.L., Troyano, A., Vilaboa, N.E
技术资料
